Compare FARM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FARM | IGC |
|---|---|---|
| Founded | 1912 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 33.8M |
| IPO Year | N/A | N/A |
| Metric | FARM | IGC |
|---|---|---|
| Price | $1.52 | $0.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.75 | ★ $4.00 |
| AVG Volume (30 Days) | 77.3K | ★ 465.5K |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $338,816,000.00 | $1,106,000.00 |
| Revenue This Year | $5.27 | $3.54 |
| Revenue Next Year | $3.78 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $0.25 |
| 52 Week High | $3.29 | $0.50 |
| Indicator | FARM | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 25.76 |
| Support Level | $1.49 | $0.30 |
| Resistance Level | $1.62 | $0.34 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 40.00 | 3.87 |
Farmer Bros Co is engaged in manufacturing, wholesaling, and distributing coffee, tea, and culinary products to food-service establishments and retailers in the United States. The company's customers include restaurants, hotels, offices, casinos, convenience stores, healthcare facilities, and other food-service providers. The company's product categories include roast and ground coffee, frozen liquid coffee, flavored and unflavored iced and hot teas, culinary products, spices, and other beverages, such as cappuccino, cocoa, granitas, and ready-to-drink iced coffee.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.